Plasma adrenomedullin level and development of hypertension
Plasma adrenomedullin level and development of hypertension
复制标题
DOI：
10.1038/sj.jhh.1002033
复制
发表时间：
2006-08-01
影响因子：
2.7
通讯作者：
Eto, T.
中科院分区：
文献类型：
--
作者：
Kato, J.;Kitamura, K.;Eto, T.
肾上腺髓质素（adrenomedullin，AM）是一种抑制血压升高和高血压器官损害进展的因子，高血压患者血浆AM水平升高。本研究的目的是探讨血浆AM水平的升高是否先于高血压的发展。根据血浆中AM浓度中位数（11.9fmol/ml）将血压正常、无明显心血管或肾脏疾病的当地居民（n=177）分为低AM组和高AM组，并随访3年以了解高血压的发展情况。高AM组高血压患病率高于低AM组（27.8%比11.5%，P
The hypotensive peptide adrenomedullin (AM) is assumed to act as a factor inhibitory on elevation of blood pressure and on progression of the hypertensive organ damage, and plasma AM levels are elevated in patients with hypertension. The aim of the present study is to explore whether or not a rise in plasma AM levels precedes the development of hypertension. Normotensive local residents without apparent cardiovascular or renal disease (n=177) were divided into low and high AM groups based on the median concentration of AM in plasma (11.9 fmol/ml), and followed up for 3 years for development of hypertension. The incidence of hypertension was higher in the residents with high AM than low AM levels (27.8 vs 11.5%, P